Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

InnoCare to Start China Trial of TYK2 Inhibitor for Autoimmune Diseases

publication date: May 18, 2021

Beijing's InnoCare reported China approved a Phase I trial of its novel oral TYK2 (Tyrosine Kinase 2) inhibitor, the company’s fifth innovative drug to start clinical trials. ICP-332 is designed to be a potent and selective TYK2 inhibitor with a 400 fold improvement in selectivity against JAK2 to avoid the adverse events associated with non-selective JAK inhibitors. It will be tested as a therapy for autoimmune diseases such as psoriasis and atopic dermatitis. No selective TYK2 inhibitors are approved globally. More details....

Stock Symbol: (HK: 09969)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.